Balanced news tone
News Sentiment
RGEN sentiment intelligence
Repligen Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+1.3% over one week, +10.5% over four weeks, trend inactive, and near fair-value range.
Repligen (RGEN) Stock May Trade At Fair Value But At A Sales Premium
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Repligen (RGEN) Stock May Trade At Fair Value But At A Sales Premium
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 16 Jul 2026 01:03
- Source
- simplywall.st
Repligen to report Q2 2026 financial results on July 28
Repligen Corporation is set to announce its second-quarter 2026 financial results on July 28, 2026, covering the period ended June 30, 2026. The company will issue a press release before market open, followed by a conference call at 8:00 a.m. ET to discuss the results and provide
- Tone
- Positive 75/100
- Event
- Earnings
- Published
- 15 Jul 2026 14:11
- Source
- scanx.trade
Repligen Schedules 8 a.m. ET Webcast for July 28 Results
Repligen (NASDAQ: RGEN) announced it will report its Q2 2026 financial results on Tuesday, July 28, 2026. A press release will be issued before market open, followed by a conference call and webcast at 8:00 a.m. ET to discuss business updates and results for the quarter ended Jun
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 12:11
- Source
- Stock Titan
Repligen to Report Second Quarter 2026 Financial Results
Repligen Corporation (NASDAQ:RGEN) announced it will report its second quarter 2026 financial results on Tuesday, July 28, 2026. The company will issue a press release before market open and host a conference call at 8:00 a.m. ET to discuss business updates and financial results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 11:11
- Source
- GlobeNewswire
ETFs Investing in Repligen Corporation Stocks
This article lists numerous Exchange Traded Funds (ETFs) that hold Repligen Corporation stocks, categorizing them by issuer, management style, focus, expense ratio, and assets under management (AUM). It provides key financial metrics for each ETF, including market value of Replig
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 19:42
- Source
- TradingView
Repligen Stock And 2 Dollar Beneficiaries Gaining Attention After Fed Rate Shift
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 13:02
- Source
- simplywall.st
Can Repligen (RGEN) Stay Undervalued On Russell Index Removals And Margin Concerns?
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 10 Jul 2026 03:59
- Source
- simplywall.st
Is It Too Late to Buy Repligen Corp (RGEN) After 4.7% Rally? GF Value Says Undervalued
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Jul 2026 22:54
- Source
- GuruFocus
Repligen stock trades steadily as bioprocessing demand shapes investor focus
Repligen stock (RGEN) is influenced by its role in the high-growth bioprocessing sector, where demand for biologics and advanced therapies drives recurring revenue. Investors focus on long-term factors like margins, capacity expansion, and broad biologics demand, rather than shor
- Tone
- Positive 72/100
- Event
- Earnings
- Published
- 09 Jul 2026 17:35
- Source
- Ad-hoc-news.de
(RGEN) and the Role of Price-Sensitive Allocations
This article provides an in-depth stock analysis for Repligen Corporation (NASDAQ: RGEN), highlighting neutral near-term readings and strong mid-term sentiment that may be stalling. It details AI-generated trading strategies including position trading, momentum breakout, and risk
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 16:10
- Source
- Stock Traders Daily
Should Repligen's (RGEN) Russell Growth Index Removal Require Action From Current Investors?
Repligen (RGEN) was removed from multiple Russell growth benchmarks, including the Russell 1000 Growth and 3000 Growth Indexes, which may affect its liquidity and shareholder base. While this shift doesn't alter immediate operational drivers like order trends or margins, it highl
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 08 Jul 2026 05:10
- Source
- Simply Wall Street
Repligen Corp business overview and stock context
Repligen Corp specializes in bioprocessing technologies for biologic drug production, supplying equipment and solutions to pharmaceutical and biotech companies. Its business model focuses on filtration, separation, and fluid management systems, benefiting from the growing demand
- Tone
- Positive 67/100
- Event
- Macro sensitivity
- Published
- 07 Jul 2026 22:46
- Source
- AD HOC NEWS
REPLIGEN CORP : BENCHMARK RAISES TO BUY FROM HOLD
Benchmark has upgraded its rating for Repligen Corporation from Hold to Buy. This indicates an increased positive outlook on the company's stock performance.
- Tone
- Positive 72/100
- Event
- Guidance
- Published
- 07 Jul 2026 20:11
- Source
- Moomoo
Benchmark Upgrades Repligen to Buy From Hold, Price Target is $185
- Tone
- Positive 58/100
- Event
- Analyst action
- Published
- 07 Jul 2026 11:43
- Source
- MT Newswires
Evercore Maintains Repligen(RGEN.US) With Buy Rating, Raises Target Price to $160
Evercore has reiterated its Buy rating on Repligen (RGEN.US) and increased its target price to $160. This reflects the firm's continued confidence in the company's financial prospects and market position.
- Tone
- Positive 73/100
- Event
- Analyst action
- Published
- 07 Jul 2026 06:10
- Source
- Moomoo
If You Invested $1,000 in Repligen (RGEN)
This article analyzes the historical performance of investing $1,000 in Repligen (RGEN) over 1, 5, and 10 years, detailing the total return and Compound Annual Growth Rate (CAGR). It also provides an annual performance comparison of RGEN against the S&P 500 and offers a company o
- Tone
- Positive 63/100
- Event
- Market update
- Published
- 04 Jul 2026 08:41
- Source
- Stock Titan
Is Repligen Corporation (RGEN) A Good Stock To Buy Now?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 03 Jul 2026 07:00
- Source
- Market source
Here’s Why Repligen Corp. (RGEN) Fell 28% in Q1
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Market source
Repligen Corporation(NasdaqGS: RGEN) dropped from Russell Midcap Growth Benchmark
Repligen Corporation (NasdaqGS: RGEN) has been removed from the Russell Midcap Growth Benchmark. This news follows a series of recent events for the company, including presentations at healthcare conferences and its Q1 2026 earnings report, where it posted better-than-expected ad
- Tone
- Negative 28/100
- Event
- Earnings
- Published
- 29 Jun 2026 16:56
- Source
- www.marketscreener.com
Price to sales forward of Repligen Corporation – NASDAQ:RGEN
The article provides a financial metric for Repligen Corporation (NASDAQ: RGEN), specifically its forward price-to-sales ratio. It indicates that the market was closed at the time of publication and there were no trades. The content offers a snapshot of a financial data point for
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 04:10
- Source
- TradingView
Price to earnings forward of Repligen Corporation – NASDAQ:RGEN
This page provides financial information for Repligen Corporation (NASDAQ:RGEN), specifically focusing on its forward Price to Earnings (P/E) ratio. It indicates that the market for RGEN is currently closed with no trades. The content is primarily a data placeholder from TradingV
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 21:41
- Source
- TradingView
Price to book forward of Repligen Corporation – BX:RGN
The article displays the "Price to book forward" for Repligen Corporation (RGN) on the BX Swiss exchange. It notes that the market is currently closed with no trades. The content primarily shows financial data available through TradingView, including a historical overview, and hi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 13:41
- Source
- TradingView
Enterprise value to EBITDA forward of Repligen Corporation – NASDAQ:RGEN
This article displays the enterprise value to EBITDA forward for Repligen Corporation, traded as RGEN on the Nasdaq Stock Market. It presents the period, value, and change information for this financial metric. The content is primarily a data point from TradingView's financial an
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 12:10
- Source
- TradingView
Enterprise value to revenue forward of Repligen Corporation – BX:RGN
The article focuses on the "Enterprise value to revenue forward" metric for Repligen Corporation, traded on the BX Swiss exchange under the symbol RGN. It presents this financial data point for the company. The content primarily highlights where to find this financial detail with
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 10:10
- Source
- TradingView
Repligen Corporation Actuals & Estimates (DUS:RGN)
This article provides financial actuals and estimates for Repligen Corporation (DUS:RGN), including income statement, balance sheet, and cash flow data, alongside analyst price targets. It covers frequently asked questions regarding its stock ticker, forecast, historical prices,
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 27 Jun 2026 03:41
- Source
- TradingView
Insider Sell: Jason Garland Sells Shares of Repligen Corp (RGEN)
Jason Garland, CFO of a Repligen Corp (RGEN) subsidiary, sold 733 shares of the company on June 25, 2026. This transaction leaves him with 19,359 shares. The stock, trading at $145 with a market cap of $8.292 billion, is considered modestly undervalued with a price-to-GF-Value ra
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 02:09
- Source
- GuruFocus
Repligen Corporation Actuals & Estimates (NASDAQ:RGEN)
This article provides an overview of Repligen Corporation (NASDAQ: RGEN) stock, including its current price, market capitalization, and historical performance. It details financial actuals and estimates, analyst forecasts for future price targets, and information on earnings repo
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 26 Jun 2026 21:09
- Source
- TradingView
Repligen (RGEN) CFO completes 733-share Rule 10b5-1 stock sale
Repligen's CFO, Jason K. Garland, sold 733 shares of the company's common stock at $145 per share in a pre-planned transaction. This sale, totaling $106,285, was executed under a Rule 10b5-1 trading plan adopted on December 8, 2025. Following the transaction, Garland directly own
- Tone
- Negative 40/100
- Event
- Market update
- Published
- 26 Jun 2026 20:09
- Source
- Stock Titan
Repligen Corporation Shs Unsponsored Brazilian Depositary Receipt Repr 0.033333 Sh Actuals & Estimates (BMFBOVESPA:R2GE34) — TradingView
The article provides an overview of Repligen Corporation (BMFBOVESPA:R2GE34) on TradingView, focusing on its financial actuals and estimates. It highlights features for exploring reported financial data, analyst estimates across various statements, and comparing actual results wi
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 08:40
- Source
- TradingView
RGN Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast and financial overview for Repligen Corporation (RGN) stock. It includes analysts' price targets, past performance data, earnings reports, revenue figures, and other key financial metrics. The article also addresses frequently asked quest
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 06:40
- Source
- TradingView